📢 ¡Ya disponible la edición 2025 del Manual de Recomendaciones GEMFIN en Neoplasias Mieloproliferativas Crónicas Filadelfia Negativas!
Una herramienta clave para la práctica clínica.
📘 Descárgalo aquí 👉 https://t.co/GlS9nW53nd
#GEMFIN#MPN#Hematología@sehh_es@HematoRYC
CONGRESS | #ASH24 | PRESENTATION
Marta Santaliestra @HematologiaMT shares findings from an analysis of the prognostic impact of achieving complete hematological response (CHR) and resistance/intolerance (R/I) to HU in patients from the Spanish registry of ET (N = 1,080).
CHR with first-line HU is a relevant prognostic factor that correlates with significantly improved survival and a lower rate of disease progression in pts categorized as high- and intermediate-risk according to revised IPSET-thrombosis stratification.
Follow our live feed for more updates: https://t.co/NqDgLO6DlQ
#MPN #MPNsm #MedicalCongress
👏La nostra enhorabona a la Dra. @martagarrote per la lectura de la seva tesi doctoral titulada: “Caracterització i classificació genòmica de les neoplàsies mieloproliferatives”, i al seu director el Dr. ‘Álvarez-Larrán.
Felicitats per aquest merescut èxit 🎓
@hospitalclinic
On behalf of my collegues I'm very happy to share our latest publication in @BMTjournal about EASIX and cardiac adverse events in allo-HCT🥳🥳
Thanks to @QueraltSalas for your knowledge, advices and patience😜
#bmt#hematology#alloHCT
…https://t.co/EI5lL1DQA3
Delighted to share our last manuscript from @espGELMC “Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors” @HematoRYC @sehh_es @icmlf @Aelemic https://t.co/nX6hAk3HHW